# Early-onset colorectal cancer may be its own distinct disease > Colorectal cancer has become the leading cause of cancer death among Americans under 50, an alarming statistic that has pushed the scientific - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Note - Published: 2026-07-05 - Canonical URL: https://mad-max.co/en/article/le-cancer-colorectal-precoce-serait-une-maladie-a-part-entiere ## Key takeaways - Colorectal cancer is now the leading cause of cancer death among Americans under 50, and the trend has been observed across Western countries for several years. - A study in the International Journal of Molecular Sciences, led by Sophia Tsokkou's team at Aristotle University of Thessaloniki, found increased chromosomal instability and amplification of genes such as MYC, RAD21, GNAS and MAPK1. - These early-onset tumors show a "cold" immune environment, which may mean resistance to certain immunotherapies, particularly in microsatellite-stable cases. - Roughly one-third of eligible Americans, over fifty million people, are not getting screened, and a larger ESMO Open study of 1,209 patients found a median overall survival of 35 months versus 41 months for older patients. - Preliminary work points to ferroptosis vulnerability in tumors with PIK3CA mutations, with a possible aspirin combination, but this remains at an early research stage. ## Introduction: a worrying trend among adults under **50** ### A cancer striking increasingly young people **Colorectal cancer** has become the leading cause of cancer death among Americans under **50**, an alarming statistic that has pushed the scientific community to seriously question the causes of this worrying trend observed for several years now across **Western countries**. New **research** now suggests that this early-onset **colorectal cancer** is not simply a younger version of the classic **disease**, but presents distinct **biological** characteristics that could justify a different diagnostic and therapeutic approach. ### Why this opinion piece deserves your attention I am devoting this piece to this **discovery** because it affects a generation that, historically, did not feel concerned by **colorectal cancer** screening, traditionally recommended starting at age 50 in most Western countries. This piece aims to simply explain what **science** knows today, without excessive alarmism, but with the clarity needed for everyone to understand the importance of this newly documented **biological** distinction. *I find it troubling that this trend affects a **generation** that believed itself safe from this type of cancer, traditionally associated with aging. This reality forces us all to rethink our **prevention** habits.* ## What research reveals about this **biological** distinction ### Increased and distinct **chromosomal instability** A **study** published in the **International Journal of Molecular Sciences**, led by a team of **researchers** from **Aristotle University of Thessaloniki** headed by **Sophia Tsokkou**, identified increased chromosomal instability and unique genetic amplification patterns in **patients** with early-onset **colorectal cancer**. These amplification patterns notably affect genes such as **MYC**, **RAD21**, **GNAS**, and **MAPK1**, genetic markers that differ **significantly** from those generally observed in **colorectal cancer** cases diagnosed at an older age. ### A different, more resistant immune environment **Researchers** also identified what they call a **cold immune environment** in these early-onset tumors, which concretely means increased resistance to certain immunotherapy **treatments**, particularly in cases showing microsatellite stability. This observed treatment resistance poses a major **clinical** challenge, since it limits the **treatment** options available for these younger **patients**, who could otherwise benefit from many additional years of life if more effective treatments were developed specifically for this form of cancer. *I believe this **discovery** about immune resistance perfectly illustrates why medicine can no longer afford to treat every colorectal cancer the same way, regardless of the patient's age at the time of **diagnosis**.* ## The alarming numbers on missed **screening** ### More than **fifty million** unscreened Americans According to reported data, roughly one-third of Americans eligible for **colorectal cancer** screening, or more than **fifty million people**, are not currently undergoing this recommended screening, a concerning gap that could further worsen this rising trend of late **diagnoses**. This lack of widespread screening means that many **colorectal cancer** cases, including among younger patients recently identified as a distinct risk group, are only detected at an already advanced stage, considerably reducing the chances of effective treatment. ### A particular clinical profile among high-risk patients Patients at high risk of early-onset **colorectal cancer** often present tumors localized on the left side of the colon, synchronous metastases at the time of initial diagnosis, and elevated levels of **carcinoembryonic antigen (CEA)**, a biological marker used to assess the progression of this type of cancer. This distinct clinical profile could eventually help doctors more quickly identify young patients at elevated risk, even in the absence of traditional risk factors such as family history or the advanced age usually associated with this cancer. *I believe this figure of **fifty million** unscreened Americans should alarm Western public health authorities even more. Closing this screening gap could save a considerable number of lives every year.* ## Promising but still early therapeutic leads ### Vulnerability to **ferroptosis** in certain patients Researchers identified a particular vulnerability to **ferroptosis**, a specific cell-death mechanism, in tumors carrying a **PIK3CA** gene mutation, opening a potentially interesting therapeutic avenue for this specific subgroup of patients with early-onset **colorectal cancer**. Preliminary data suggest that a combination of **aspirin** and **ferroptosis** inducers could produce an interesting synergistic effect in these patients, though this avenue remains at an early research stage requiring much more rigorous clinical validation. ### A generally less favorable prognosis A larger study of **1,209 patients**, published in the journal **ESMO Open**, found that patients with early-onset **colorectal cancer** had significantly less favorable overall survival, with a median of **35 months** compared with **41 months** for patients diagnosed at an older age, a statistically significant difference. This less favorable prognosis reinforces the urgency of better understanding the distinct biological mechanisms of this form of cancer, in order to develop treatments specifically tailored to it rather than defaulting to protocols designed for older patients. *I want to be honest: these therapeutic leads remain preliminary and in no way constitute a promise of immediate cure. But they represent encouraging beginnings for a disease that has long been poorly understood in young patients.* ## What this means for future prevention ### Rethinking the recommended **screening** age These findings strengthen the case for lowering the recommended screening age for **colorectal cancer**, a shift already underway in some Western countries that have recently revised their official screening guidelines downward, generally to 45 rather than 50. I believe this evolution in screening guidelines should be accompanied by increased awareness among younger audiences, who generally do not perceive **colorectal cancer** as a relevant threat for their age group. ### The importance of reporting symptoms early Beyond systematic **screening**, experts recommend that young adults promptly report to their doctor any persistent symptom such as unexplained rectal bleeding, lasting changes in bowel habits, or persistent abdominal pain with no obvious cause. This heightened vigilance, combined with earlier **screening** in at-risk populations, could help detect more cases at an earlier, more treatable stage, thereby narrowing the prognosis gap currently observed between younger and older patients. *I believe this responsibility for vigilance should not rest solely on young patients themselves: the medical profession must also be trained to take these symptoms more seriously in a population once considered low-risk.* ## The possible role of **diet** and Western lifestyle ### A dietary hypothesis still debated among researchers Several Western research teams are currently exploring the hypothesis that dietary changes, notably rising consumption of ultra-processed foods and declining fiber intake, could contribute to this rise in early-onset **colorectal cancer** cases observed since the 1990s in several industrialized countries. This hypothesis, however, remains difficult to prove definitively, as it would require decades-long cohort studies, a complex undertaking given the often long delay between exposure to a potential risk factor and the clinical appearance of a colorectal tumor. ### **Obesity** and sedentary lifestyles as possible aggravating factors Obesity and sedentary lifestyles, two phenomena sharply on the rise in Western societies over recent decades, are also among the avenues researchers are exploring to explain this worrying trend among adults under **50**. These risk factors, well known for other chronic diseases such as **type 2 diabetes** and cardiovascular disease, could act in synergy with the recently identified genetic particularities, though no single direct causal link has yet been formally established by the scientific community. *I remain cautious about these dietary and environmental hypotheses: they are plausible, but science has not yet delivered a definitive answer. It would be dishonest to present a single explanation as established certainty.* ## Regional disparities in access to early **screening** ### Significant gaps between **Western countries** Access to **colorectal cancer** screening varies considerably from one Western country to another, with some public health systems offering free, systematic screening starting at age 45, while others still maintain the traditional threshold of 50 for lack of resources or an updated medical consensus. These regional disparities raise an important equity question, since patients with an identical risk profile could be diagnosed at very different stages depending on which Western country they live in and the **public health** policies in force locally. ### **Canada** and Quebec facing this reality In Canada, **screening** recommendations also vary by province, with some already beginning to consider lowering the recommended age, while Quebec continues to study the question in light of newly published international scientific data. This Canadian reflection fits into a broader movement seen across Western countries, where **public health** authorities must now contend with scientific data evolving faster than the usual cycles for revising clinical guidelines. *I believe Quebec should speed up its deliberations on lowering the **screening** age rather than waiting indefinitely for a perfect consensus. Every year of delay means missed diagnoses among young patients.* ## What patients and families can do right now ### Know your **family history** and talk about it Despite the absence of traditional risk factors in many patients with early-onset **colorectal cancer**, knowing your family history remains an important step everyone can take right now by openly discussing it with relatives and their family doctor. This simple step, though it does not replace formal **screening**, can help doctors better assess individual risk levels and direct certain patients toward additional testing sooner than current general guidelines would suggest. ### Don't ignore symptoms out of embarrassment or denial Many young adults delay seeing a doctor out of embarrassment over digestive symptoms, an understandable but potentially dangerous reflex given what this research reveals about the distinct and sometimes more aggressive nature of early-onset **colorectal cancer**. Breaking this taboo around digestive symptoms is, in my view, a public health priority just as important as the debate over the official **screening** age recommended by Western medical authorities. *I firmly believe embarrassment should never cost a life. Talking openly about **digestive symptoms** should become as normal as discussing blood pressure or cholesterol with a family doctor.* ## Conclusion: **cautious explanation** in the face of a real trend ### What to take away from this discovery This research confirms that early-onset **colorectal cancer** presents distinct biological characteristics that justify specific scientific and clinical attention, rather than continuing to treat it as simply a younger version of the classic disease seen in older patients. This biological distinction, while scientifically valuable, should not turn into a source of widespread panic, but rather into a reasonable call for greater vigilance and earlier **screening** among the at-risk populations identified by this research. ### **Measured hope** for the future of treatment I close this piece with **measured hope**: understanding the distinct biological mechanisms of this form of cancer represents an essential step toward developing more effective treatments better suited to the young patients affected by this disease. This new scientific understanding will take time to translate into concrete clinical benefits, but it already represents important progress in our collective ability to better understand, and eventually better treat, this worrying trend. *I close this piece convinced that we should neither panic nor ignore this signal. Western science is advancing, slowly but surely, toward a better understanding of this disease, which now affects a **generation** that believed itself safe.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - PubMed, The Molecular Signature of Early-Onset Colorectal Cancer Liver Metastases — April 2026 - The Cancer Letter, coverage on early-onset colorectal cancer as a distinct disease — July 2, 2026 ### Secondary sources - Taylor & Francis Online, additional analysis on early-onset colorectal cancer — 2026 - PubMed Central, additional study on the biological characteristics of early-onset colorectal cancer - PubMed Central, ESMO Open study on the prognosis of early-onset colorectal cancer — 2025 - Aristotle University of Thessaloniki, institutional page of the research team --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/le-cancer-colorectal-precoce-serait-une-maladie-a-part-entiere